Title: Seroprevalence of chikungunya and o'nyong-nyong viruses in Senegal, West

Africa

Authors: Prince Baffour Tonto[1,2], Mouhamad Sy[3], Ibrahima Mbaye Ndiaye[3], Mariama

Toure[3], Amy Gaye[3], Mariama Aidara[3], Amadou Moctar Mbaye[3], Abdoulaye Kane Dia[3,4],

Mamadou Alpha Diallo[3], Jules Francois Gomis[3], Mamadou Samba Yade[3], Younous

Diedhiou[3], Baba Dieye[3], Khadim Diongue[3], Mame Cheikh Seck[3], Aida S. Badiane[3],

Bobby Brooke Herrera[1,2]*, Daouda Ndiaye[3]

Affiliations:

1 Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA

2 Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases

and Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical

School, New Brunswick, NJ, USA

3 International Research Training Center on Genomics and Health Surveillance

(CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal

4 Laboratoire d'ecologie vectorielle et parasitaire

*Corresponding Author: BBH, bherrera@globalhealth.rutgers.edu

Abstract

Background

Arthritogenic alphaviruses such as chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses have shown capacity to cause widespread epidemics, with recurrent and sporadic outbreaks occurring throughout sub-Saharan Africa.

Methods

We analyzed the seroprevalence for CHIKV and ONNV in 470 non-febrile subjects from three regions in Senegal (Sindia, 2018; Thies, 2018; and Kedougou, 2022/2023) using retrospective samples. We assessed the presence of anti-CHIKV IgG and neutralizing titers against CHIKV and ONNV via enzyme-linked immunosorbent assay (ELISA) and microneutralization tests, respectively, and determined risk factors of CHIKV and ONNV exposure by binary logistic regression.

Results

The overall seroprevalence of anti-CHIKV IgG was 24.89% (117/470). Regional seroprevalences were 14.89% (14/94) in Sindia, 28.72% (27/94) in Thies, and 26.95% (76/282) in Kedougou. Among CHIKV IgG-positive samples, 29.91% (35/117) and 39.32% (46/117) had neutralizing antibodies against CHIKV and ONNV, respectively. Of the remaining samples, 20.51% (24/117) were equivocal and 10.26% (12/117) were negative. Multivariate analysis showed that residence in Thies significantly increased the likelihood of CHIKV infection (OR, 3.878; 95% CI: 0.783-19.205), whereas prior malaria infection reduced it (aOR, 0.121; 95% CI: 0.049-0.300). Conversely, older age (OR, 7.896; 95% CI: 1.500-41.556) and residence in Kedougou (OR, 3.180; 95% CI:

0.824-12.276) were significant risk factors for ONNV infection, with prior malaria

infection also linked to higher ONNV susceptibility (aOR, 6.961; 95% CI: 2.456-19.732).

Conclusions

Our study confirms significant exposure to CHIKV and ONNV across Senegal,

underscoring the importance of ongoing surveillance and alphavirus testing among the

population.

Author summary

Arthritogenic alphaviruses, such as chikungunya (CHIKV) and o'nyong-nyong (ONNV)

viruses have the potential to cause widespread epidemics, with recurrent and sporadic

outbreaks occurring throughout sub-Saharan Africa. This study presents a retrospective

evaluation of CHIKV and ONNV seroprevalence among non-febrile subjects from three

regions in Senegal: Sindia, Thies, and Kedougou. Our analysis revealed regional

variation in alphavirus seroprevalence, with 29.91% of subjects exhibiting neutralizing

antibodies against CHIKV and 39.32% against ONNV. We identified that residence in

Thies was a risk factor for CHIKV, while residence in Kedougou, a history of malaria,

and older age were risk factors for ONNV. These findings suggest significant exposure

to CHIKV and ONNV across Senegal, underscoring the importance of ongoing

surveillance and alphavirus testing among the population.

Introduction

Arboviruses transmitted by mosquitoes pose a growing global health threat, significantly impacting morbidity and mortality. Among these, chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses are notable members of the alphavirus genus, recognized for their substantial effects on human health (1, 2). CHIKV, first isolated in Tanzania in 1952, has caused major outbreaks across Africa, Asia, and the Americas (3-5). Its transmission primarily involves *Aedes* mosquitoes, and its capacity for widespread dissemination was highlighted by the 2004 epidemic that originated in Kenya and rapidly extended to various regions, including the Indian Ocean islands and South and Southeast Asia (1, 5-7). By 2011, CHIKV reached the Western Hemisphere, spreading through the Caribbean and South America by 2014, resulting in hundreds of thousands of infections (8-10).

ONNV, identified in Uganda in 1959, has caused significant epidemics primarily in East and West Africa, with major outbreaks recorded in the 1950s and early 1990s (11-13). Transmitted by *Anopheles* mosquitoes, ONNV remains largely confined to the African continent (6). The first major epidemic occurred from 1959 to 1962, affecting over 2 million people across East and West Africa (14, 15). A subsequent outbreak from 1996 to 1997 primarily impacted Uganda, Kenya, and Tanzania, with infection rates ranging from 45-68% (14, 16). Despite its geographical confinement, ONNV has been detected in travelers returning from endemic regions (17).

Clinically, infections with CHIKV and ONNV are generally self-limiting but can present a spectrum of symptoms including fever, arthralgia, rash, headache, and malaise (18, 19). CHIKV is particularly associated with persistent arthralgia in patients

(20). Although ONNV is endemic to Africa, comprehensive data on its morbidity and

mortality are limited due to inadequate surveillance. The clinical features of alphavirus

infections closely resemble those caused by other pathogens including *Plasmodium*

(malaria) or *Salmonella* (typhoid fever) species, which are endemic in many West

African countries (21-26). This symptom overlap complicates diagnosis and can lead to

underreporting of CHIKV and ONNV, as their symptoms may be misattributed to other

febrile illnesses.

In West Africa, including Senegal, autochthonous cases of CHIKV have been

reported since 1960, with periodic outbreaks continuing up to 2023 (27-31). Despite

these occurrences, current data on the seroprevalence of CHIKV and ONNV in Senegal

remains limited. This study aims to address this knowledge gap by investigating the

seroprevalence of CHIKV and ONNV in Senegal. Given the antigenic similarities

between these viruses, our approach focuses on using microneutralization assays to

help differentiate between them to provide a more in-depth understanding of their

prevalence. By enhancing our knowledge of the epidemiological landscape of CHIKV

and ONNV in Senegal, we hope to inform public health strategies and contribute

valuable insights into the broader context of arboviral transmission in West Africa.

Methods

Study Population and Ethics Statement

The samples included in our study were originally collected as part of malaria

and non-malarial surveillance among residents of Thies, Sindia, and Kedougou,

Senegal. Samples from Thies and Sindia were part of the surveillance of non-malarial

febrile illnesses, while samples from Kedougou were part of genomic surveillance of

malaria. Informed consent was obtained from all subjects and/or their legal guardians

for the initial sample collection as well as for its future use. All methods were performed

in accordance with the guidelines and regulations set forth by the Declaration of

Helsinki. The primary studies under which the samples and data were collected

received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol

numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding

data were banked and de-identified prior to the analyses.

CHIKV viral like particle (VLP) ELISA

CHIKV VLPs (20 ng per well; Native Antigen) were coated onto Nunc Maxisorp

96-well plates (ThermoFisher) overnight, followed by blocking (1X PBST, 1% BSA;

ThermoFisher) for 1 hour, then washing (1X PBST three times) and incubation with

primary antibodies for 2 hours (serum at 1:400 dilution) at room temperature. The plates

were washed three times with 1X PBST and bound sera were reacted with secondary

antibodies (anti-human IgG conjugated with horseradish peroxidase [HRP];

ThermoFisher), according to the manufacturer's instructions. The plates were washed

three more times and allowed to develop with 1-Step TMB ELISA Substrate

(ThermoFisher), according to the manufacturer's instructions. The OD at 450 nm was

read with a reference wavelength of 650 nm using an ELISA reader (Diasource). We

interpreted the ELISA assay as follows: 1) sample absorbance / negative control

absorbance ≤ 1.5, negative; 2) sample absorbance / negative control absorbance > 1.5,

positive.

Serum Microneutralization Assays

Microneutralization assays were performed to detect neutralizing antibodies against CHIKV and ONNV in samples that were IgG positive for CHIKV VLP. Sera were diluted in a two-fold series from 1:40 to 1:10,240 in PBS in a 96-well plate. For each dilution, contact was performed with 100 plaque forming units (PFU) of CHIKV (BEI Resources: NR-56523) or ONNV (BEI Resources: NR-51661) for one hour at 37°C in a 5% CO_2 incubator. The complexes were then added to Vero cells (ATCC) CCL-81, 1.3 x 10^5 cells per well. After 3-4 days of incubation, the cytopathogenic effects were investigated by 0.2% crystal violet (SigmaAldrich) staining. After staining for 2-4 hours, the plates were washed with copious amounts of tap water. For negative controls, at least 3 alphavirus-naïve serum samples were used to incubate with CHIKV or ONNV prior to pipetting onto the Vero cells per plate. For positive controls, 100 PFU of CHIKV or ONNV without any contact with serum were placed on Vero cells in triplicate per plate.

The neutralizing titer was defined as the inverse of the highest dilution resulting in an infectious reduction of 50%. A titer lower than 1:40 was considered as negative if cytopathogenic effects were not observed. Samples were considered as positive if the titer was ≥1:40, i.e., positive for ONNV if ONNV titers were at least two-fold higher than CHIKV titers, and CHIKV positive if CHIKV titers were at least four-fold higher than ONNV titers (32). The threshold was lower for ONNV than CHIKV because of the unique one-way cross-reactivity between CHIKV and ONNV, i.e., CHIKV antibodies are more likely to cross-react with ONNV antigens than ONNV antibodies with CHIKV antigens (33). All other results were interpreted as equivocal. 20 Senegalese serum

samples that were previously determined to be alphavirus-naïve, were used to validate

the assay. Each assay used at least 4 alphavirus-naïve serum samples as negative

controls.

Statistical Analysis

Categorical variables are represented as case counts and proportions. To

estimate the association between seroprevalence of alphavirus and demographics

factors, including age group, gender, city, and malaria status, univariate and multivariate

binary logistic regression analyses were performed. The adjusted odd ratios of the

independent variables were computed by adjusting for age and gender as confounding

variables. Statistical analyses were conducted using IBM SPSS statistics software

version 28. The map of Senegal, heatmap, and graph representing rates and

percentages of CHIKV and ONNV neutralizing antibodies were generated using R

version 4.3.2 and Prism version 10.2.0.

Results

A total of 470 samples collected from non-febrile subjects were included in the

study. These samples were collected from three locations in Senegal: Sindia (n=94),

Thies (n=94), and Kedougou (n=282) (Table 1). The samples from Sindia and Thies

were malaria-negative by rapid diagnostic testing, whereas the samples from Kedougou

were from subjects with malaria (Table 1). Participants' ages ranged from 6 months to

85 years, with an overall median age of 21 years. The study population was comprised

of 44.89% females (n=211) (Table 1).

Table 1. Baseline characteristics and chikungunya virus (CHIKV) and o'nyong-nyong virus (ONNV) serology

Characteristic and Serology	Sindia (n=94)	Thies (n=94)	Kedougou (n=282)	Total (N=470)
Demographics				
Year(s) samples collected	2018	2018	2022-2023	
Median age (range)	24 (2-70)	20 (6 months-69)	21 (2-85)	21 (6 months-85)
% Female (number)	41.49 (39)	54.25 (51)	42.91 (121)	44.89 (211)
Malaria status, number (%)				
Positive	0 (0)	0 (0)	282 (100)	282 (60)
Negative	94 (100)	94 (100)	0 (0)	188 (40)
CHIKV VLP IgG, number (%)				
Positive	14 (14.89)	27 (28.72)	76 (26.95)	117 (24.89)
Negative	80 (85.11)	67 (71.28)	206 (73.05)	353 (75.11)
NT50, number/total (%)				
CHIKV	6/14 (42.86)	18/27 (66.67)	11/76 (14.47)	35/117 (29.91)
ONNV	4/14 (28.57)	4/27 (14.81)	38/76 (50)	46/117 (39.32)
Equivocal	4/14 (28.57)	5/27 (18.52)	15/76 (19.74)	24/117 (20.51)
Negative	0 (0)	0 (0)	12/76 (15.79)	12/117 (10.26)

Among the samples tested (n=470) for CHIKV VLP IgG antibodies, 117 tested

positive, indicating an overall alphavirus seroprevalence of 24.89% (Table 1).

Seroprevalence rates varied by location. Sindia had a rate of 14.89% (14/94), Thies had

28.72% (27/94), and Kedougou had 26.95% (76/282). In the serological analysis, a

multivariate logistic regression revealed that subjects over 40 years old were more likely

to have been exposed to an alphavirus, based on IgG reactivity to CHIKV VLP (OR,

2.100; 95% CI: 1.107-3.986) (S1 Table). Additionally, being a resident of Thies (OR,

2.384; 95% CI: 1.151-4.939) and Kedougou (OR, 5.591; 95% CI: 3.001-10.418) were

associated with increased odds having been exposed to an alphavirus, with the highest

risk observed in Kedougou (S1 Table). Furthermore, subjects with prior history of

malaria were also more likely to have been exposed to an alphavirus (aOR, 3.465; 95%

CI: 2.253-5.328) (S1 Table).

The prevalence of neutralizing antibodies against CHIKV and ONNV varied by

location in Senegal. The prevalence rates of CHIKV neutralizing antibodies were

42.86% (6/14) in Sindia, 66.67% (18/27) in Thies, and 14.47% (11/76) in Kedougou

(Fig. 1A). For ONNV, the neutralizing antibody prevalence rates of were 28.57% (4/14)

in Sindia, 14.81% (4/27) in Thies, and 50% (38/76) in Kedougou (Table 1, Fig. 1A).

Overall, 29.91% (35/117) had neutralizing antibodies against CHIKV, 39.32% (46/117)

had neutralizing antibodies against ONNV, 20.51% (24/117) were equivocal for both

CHIKV and ONNV, and 10.26% (12/117) were negative (Table 1). Moreover, of the

subjects with CHIKV neutralizing antibodies, 94.29% had cross-neutralizing antibodies

against ONNV (Fig. 1B-C). However, of the subjects with ONNV neutralizing antibodies,

only 53.33% had cross-neutralizing antibodies against CHIKV (Fig. 1B-C).

Fig. 1. Antibody neutralization against chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses in Senegal. A) Map depicts locations in Senegal (Sindia, Thies, and Kedougou) where samples were collected from non-febrile subjects. For each location, donut charts represent number and corresponding percentages of subjects with neutralizing antibodies against CHIKV and ONNV or equivocal and negative results. B) CHIKV virus-like particle IgG-positive samples were tested for neutralizing antibodies against CHIKV and ONNV. Colors depict the 50% neutralizing antibody titers (NT50), each row represents one individual, and each column is the titer to CHIKV or ONNV. C) The percentage of NT50-confirmed CHIKV or ONNV subjects with cross-neutralizing antibodies to the heterologous virus.

Multivariate logistic regression analyses revealed that subjects from Thies were

more likely to be infected with CHIKV (OR, 3.878; 95% CI: 0.783-19.205) (Table 2).

Conversely, being a resident of Kedougou (OR, 0.280; 95% CI: 0.074-1.054) and a prior

history of malaria parasite (aOR, 0.121; 95% CI: 0.049-0.300) infection were associated

with significantly lower odds of contracting CHIKV (Table 2). In contrast, subjects over

40 years of age were more likely to be infected with ONNV (OR, 7.896; 95% CI: 1.500-

41.556) (Table 3). Additionally, being a resident of Kedougou (OR, 3.180; 95% CI:

0.824-12.276) and malaria infection (aOR, 6.961; 95% CI: 2.456-19.732) were

associated with increased odds of contracting ONNV (Table 3).

255 **Table 2. Risk factors for NT50-confirmed chikungunya virus (CHIKV) infections in**

256 **Senegal**

CHIKV NT50-confirmed subjects

Variable	Univariate		Multivariate			
	OR (95% CI)	p value	aOR (95% CI)	p value	OR (95% CI)	p value
Age group						
≤ 20 years	Reference	0.255	Reference	0.268	Reference	0.688
21-40 years	1.07 (0.435-2.635)		1.067 (0.433-2.632)		1.571 (0.501-4.930)	
> 40 years	2.529 (0.818-7.826)		2.507 (0.802-7.834)		1.471 (0.362-5.978)	
Gender						
Male	Reference		Reference		Reference	
Female	1.167 (0.529-2.572)	0.702	1.049 (0.467-2.356)	0.907	1.022 (0.402-2.597)	0.964
City						
Sindia	Reference	<0.001	Reference	<0.001	Reference	<0.001
Thies	3.167 (0.827-12.126)		3.878 (0.783-19.205)		3.878 (0.783-19.205)	
Kedougou	0.237 (0.069-0.815)		0.280 (0.074-1.054)		0.280 (0.074-1.054)	
Malaria status						
No	Reference					
Yes	0.114 (0.046-0.278)	<0.001	0.121 (0.049-0.300)	<0.001	_	_

257 OR- Odd ratio; aOR- adjusted odd ratio for sex and age

280 **Table 3. Risk factors for NT50-confirmed o'nyong-nyong virus (ONNV) infections**

281 **in Senegal**

ONNV NT50-confirmed subjects

Variable	Univariate				Multi-variate	
	OR (95% CI)	p value	aOR (95% CI)	p value	OR (95% CI)	p value
Age group						
≤ 20 years	Reference	0.081	Reference	0.075	Reference	0.022
21-40 years	2.396 (1.019-5.634)		2.423 (1.028-5.713)		2.356 (0.897-6.192)	
> 40 years	2.529 (0.818-7.826)		2.623 (0.837-8.224)		7.896 (1.500-41.556)	
Gender						
Male	Reference		Reference		Reference	
Female	0.882 (0.414-1.880)	0.746	0.835 (0.380-1.835)	0.653	0.872 (0.3730-2.038)	0.751
City						
Sindia	Reference	0.003	Reference	0.002	Reference	0.002
Thies	0.313 (0.059-1.658)		0.212 (0.026-1.752)		0.212 (0.026-1.752)	
Kedougou	2.569 (0.738-8.941)		3.180 (0.824-12.276)		3.180 (0.824-12.276)	
Malaria status						
No	Reference					
Yes	4.992 (1.962-12.703)	<0.001	6.961 (2.456-19.732)	<0.001	_	_

282 OR- Odd ratio; aOR- adjusted odd ratio for sex and age

Discussion

This study provides novel insights into the seroprevalence of CHIKV and

ONNV in Senegal, revealing significant regional differences that contribute to our

understanding of arboviral dynamics in West Africa. Our findings indicate a substantial

exposure to CHIKV and ONNV, with a detected anti-CHIKV IgG seroprevalence of

24.89% (117/470) among the study population (Table 1). This suggests an entrenched

alphavirus presence that might be influencing public health without sufficient recognition

or response.

The regional seroprevalences of anti-CHIKV IgG—14.89% in Sindia, 28.72%

in Thies, and 26.95% in Kedougou—reflect notable geographical variability, consistent

with previous studies across West Africa (Table 1). The significant variation between

these regions highlights the role of local environmental and ecological factors in

arbovirus transmission dynamics.

Our multivariate analysis underscores the influence of location, age, and malaria

status on the risk of CHIKV and ONNV infection. Residents of Thies showed a three-

fold increase in the likelihood of CHIKV infection compared to other regions, a finding

that could be attributed to specific local vector ecology or differences in human activities

that increase exposure to vectors (Table 2). Conversely, a history of malaria was

associated with a reduced likelihood of CHIKV exposure, suggesting possible cross-

immunity or behavioral adaptations that reduce exposure to vectors shared by both

pathogens (Table 2). For ONNV, older age and residence in Kedougou significantly

increased exposure risk, with Kedougou's unique environmental conditions potentially

facilitating higher mosquito density and virus transmission (Table 3).

Furthermore, the presence of neutralizing antibodies in our sample cohort—

29.91% for CHIKV and 39.32% for ONNV—underscores ongoing virus circulation and

potential for outbreaks (Fig. 1A). Notably, the high prevalence of ONNV neutralizing

antibodies in Kedougou (50%) compared to other regions points to specific regional

vulnerabilities, possibly driven by the overlapping mosquito vectors for malaria and

ONNV (Fig. 1A). We also found that a high percentage (94.29%) of subjects with CHIKV

neutralizing antibodies also had cross-neutralizing antibodies against ONNV (Fig. 1B-

C). Conversely, a smaller proportion (53.33%) of those with ONNV neutralizing

antibodies demonstrated cross-neutralization against CHIKV (Fig. 1B-C). These findings

corroborate a directional bias in immune cross-reactivity, where CHIKV exposure might

confer broader immunity, potentially impacting subsequent ONNV infection dynamics.

This asymmetric cross-reactivity could also be due to structural similarities in the

viral envelope proteins of CHIKV and ONNV, with CHIKV eliciting a broader neutralizing

response (33). This phenomenon is crucial for diagnostic tests, which may need

differentiation between past infections of these two viruses based on neutralizing

antibody profiles. Moreover, understanding the mechanisms behind this differential

cross-reactivity could guide vaccine strategies where a vaccine against one virus might

offer partial protection against the other, hence optimizing the control measures for both

viruses in regions where they co-circulate.

The higher prevalence observed in older age groups for CHIKV supports the

notion that cumulative exposure over time contributes to higher exposure rates. This

demographic insight is crucial for developing targeted public health strategies,

especially for vaccine deployment and vector control initiatives. The absence of a

similar age-related pattern for ONNV suggests different dynamics, potentially influenced

by sporadic outbreaks rather than continuous exposure.

Limitations of our study include the retrospective nature of sample collection,

which may not capture the most recent trends in virus circulation, and the absence of

entomological data to directly correlate vector abundance with seroprevalence rates.

Moreover, without concurrent clinical data, we cannot definitively link our serological

findings to symptomatic disease cases, potentially underestimating the true burden of

these infections. Also, IgG positivity does not necessarily reflect ongoing acute

infections but generally is a sign of previous exposure to the virus (resolved infection).

The insights into antibody cross-reactivity are essential for the interpretation of

seroprevalence data in regions endemic to both viruses, as they could lead to

overestimations of immunity against one virus due to past exposure to the other. This is

particularly relevant in vaccine efficacy trials and in the evaluation of natural immunity in

the population.

Conclusions drawn from our research illustrate the persistent circulation of

CHIKV and ONNV in Senegal, necessitating sustained surveillance and public health

preparedness to mitigate the impact of these and other arboviruses. The findings also

emphasize the importance of ecological and demographic factors in shaping the

epidemiology of these diseases, highlighting the need for comprehensive arbovirus

control strategies that integrate vector management with community health initiatives.

Future studies should aim to incorporate entomological and clinical data to provide a

more holistic understanding of the transmission dynamics and to facilitate the

development of targeted interventions, including vaccines and therapeutic measures.

Acknowledgements

We would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson

Medical School, and the Child Health Institute of New Jersey.

Conflicts of Interest

BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company that develops

diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.

Author Contributions

Conceptualization: BBH

Data curation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

MCS, ASB, BBH, DN

Formal analysis: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD,

KD, MCS, ASB, BBH, DN

Funding acquisition: BBH, DN

Investigation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

MCS, ASB, BBH, DN

Methodology: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

MCS, ASB, BBH, DN

Project administration: BBH, DN

Resources: BBH, DN

Software: PBT, MS, BBH

Supervision: BBH, MS, DN

Validation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

MCS, ASB, BBH, DN

Visualization: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

MCS, ASB, BBH, DN

Writing – original draft: PBT, BBH

Writing – review & editing: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY,

YD, BD, KD, MCS, ASB, BBH, DN

References

1.   Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al.

GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2:

Epidemiological distribution of o'nyong-nyong virus. Antiviral Res. 2019;172:104611.

2.   Zaid A, Burt FJ, Liu X, Poo YS, Zandi K, Suhrbier A, et al. Arthritogenic

alphaviruses: epidemiological and clinical perspective on emerging arboviruses. Lancet

Infect Dis. 2021;21(5):e123-e33.

3.   Renault P, Balleydier E, D'Ortenzio E, Baville M, Filleul L. Epidemiology of

Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Med Mal

Infect. 2012;42(3):93-101.

4.   Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus:

mapping the 64-year history. Int J Infect Dis. 2017;58:69-76.

5.   Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and

Its Spread to New Regions in 2013-2014. J Infect Dis. 2016;214(suppl 5):S436-S40.

6.   Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, et al.

GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5:

Entomological aspects. Antiviral Res. 2020;174:104670.

7.   Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al.

Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,

October 2004. Am J Trop Med Hyg. 2008;78(2):333-7.

8.   Fischer M, Staples JE, Arboviral Diseases Branch NCfE, Zoonotic Infectious

Diseases CDC. Notes from the field: chikungunya virus spreads in the Americas -

Caribbean and South America, 2013-2014. MMWR Morb Mortal Wkly Rep.

2014;63(22):500-1.

9.   Manzoor KN, Javed F, Ejaz M, Ali M, Mujaddadi N, Khan AA, et al. The global

emergence of Chikungunya infection: An integrated view. Rev Med Virol.

2022;32(3):e2287.

10.   Teixeira MG, Andrade AM, Costa Mda C, Castro JN, Oliveira FL, Goes CS, et al.

East/Central/South African genotype chikungunya virus, Brazil, 2014. Emerg Infect Dis.

2015;21(5):906-7.

11.   Corbet PS, Williams MC, Gillett JD. O'Nyong-Nyong fever: an epidemic virus

disease in East Africa. IV. Vector studies at epidemic sites. Trans R Soc Trop Med Hyg.

1961;55:463-80.

12.   Williams MC, Woodall JP, Corbet PS, Gillett JD. O'nyong-Nyong Fever: An

Epidemic Virus Disease in East Africa. 8. Virus Isolations from Anopheles Mosquitoes.

Trans R Soc Trop Med Hyg. 1965;59:300-6.

13.   Lanciotti RS, Ludwig ML, Rwaguma EB, Lutwama JJ, Kram TM, Karabatsos N,

et al. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence:

genetic characterization of the virus. Virology. 1998;252(1):258-68.

14.   Rezza G, Chen R, Weaver SC. O'nyong-nyong fever: a neglected mosquito-

borne viral disease. Pathog Glob Health. 2017;111(6):271-5.

15.   Williams MC, Woodall JP, Gillett JD. O'nyong-Nyong Fever: An Epidemic Virus

Diesease in East Africa. Vii. Virus Isolations from Man and Serological Studies up to

July 1961. Trans R Soc Trop Med Hyg. 1965;59:186-97.

16.   Kiwanuka N, Sanders EJ, Rwaguma EB, Kawamata J, Ssengooba FP, Najjemba

R, et al. O'nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and

validation of a clinical case definition for surveillance purposes. Clin Infect Dis.

1999;29(5):1243-50.

17.   Tappe D, Kapaun A, Emmerich P, Campos Rde M, Cadar D, Gunther S, et al.

O'nyong-nyong virus infection imported to Europe from Kenya by a traveler. Emerg

Infect Dis. 2014;20(10):1766-7.

18.   Johnson BK. O'nyong-nyong virus disease. Arboviruses: CRC Press; 2019. p.

217-24.

19.   Kucharz EJ, Cebula-Byrska I. Chikungunya fever. Eur J Intern Med.

2012;23(4):325-9.

20.   Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al.

Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal

study. PLoS neglected tropical diseases. 2013;7(3):e2137.

21.   Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, et al. A

multicountry molecular analysis of Salmonella enterica serovar Typhi with reduced

susceptibility to ciprofloxacin in sub-Saharan Africa. Clinical Infectious Diseases.

2016;62(suppl_1):S42-S6.

22.   Badiane AS, Ngom B, Ndiaye T, Cunningham D, Campbell J, Gaye A, et al.

Evidence of Plasmodium vivax circulation in western and eastern regions of Senegal:

implications for malaria control. Malaria Journal. 2024;23(1):149.

23.   Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An

epidemiological study to assess Plasmodium falciparum parasite prevalence and

malaria control measures in Burkina Faso and Senegal. Malaria journal. 2017;16:1-12.

24.   Diallo M, Diongue K, Diagne G, Seck M, Ndiaye M, Dièye B, et al. Plasmodium

ovale wallikeri and Plasmodium ovale curtisi Malaria in Senegal in 2016. Bulletin de la

Société de pathologie exotique. 2017;110:286-90.

25.   Dromigny J-A, Perrier-Gros-Claude J-D. Antimicrobial resistance of Salmonella

enterica serotype Typhi in Dakar, Senegal. Clinical infectious diseases. 2003;37(3):465-

6.

26.   Harrois D, Breurec S, Seck A, Delauné A, Le Hello S, de La Gandara MP, et al.

Prevalence and characterization of extended-spectrum β-lactamase-producing clinical

Salmonella enterica isolates in Dakar, Senegal, from 1999 to 2009. Clinical

Microbiology and Infection. 2014;20(2):O109-O16.

27.   Dieng I, Sadio BD, Gaye A, Sagne SN, Ndione MHD, Kane M, et al. Genomic

characterization of a reemerging Chikungunya outbreak in Kedougou, Southeastern

Senegal, 2023. Emerg Microbes Infect. 2024;13(1):2373308.

28.   Pistone T, Ezzedine K, Boisvert M, Receveur MC, Schuffenecker I, Zeller H, et

al. Cluster of chikungunya virus infection in travelers returning from Senegal, 2006. J

Travel Med. 2009;16(4):286-8.

29.   Roche S, Robin Y. [Human infections by Chikungunya virus in Rufisque

(Senegal), October-November, 1966]. Bull Soc Med Afr Noire Lang Fr. 1967;12(3):490-

6.

30.   Saluzzo J, Cornet M, Digoutte J. Outbreak of a Chikungunya virus epidemic in

western Senegal in 1982. Dakar medical. 1983;28(3):497-500.

31.   Sow A, Faye O, Diallo M, Diallo D, Chen R, Faye O, et al. Chikungunya Outbreak

in Kedougou, Southeastern Senegal in 2009-2010. Open Forum Infect Dis.

2018;5(1):ofx259.

32.   LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al.

High rates of o'nyong nyong and Chikungunya virus transmission in coastal Kenya.

PLoS Negl Trop Dis. 2015;9(2):e0003436.

33.   Hoze N, Diarra I, Sangare AK, Pastorino B, Pezzi L, Kouriba B, et al. Model-

based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a

serological cross-reactivity context. Nat Commun. 2021;12(1):6735.

Supporting information

S1 Table. Risk factors for alphavirus exposure (chikungunya virus virus-like

particle IgG+) in Senegal. OR- Odd ratio; aOR- adjusted odd ratio for sex and age.